Novo Nordisk to cut insulin prices by up to 75% in 2024
Novo Nordisk is cutting the price of its insulin products by up to 75%, the company announced on Tuesday.
Beginning in January 2024, Novo Nordisk will slash the price of brand name NovoLog and NovoLog Mix 70/30 insulin products by 75%, and Novolin and Levemir products by 65%.
A Novo Nordisk spokesperson said the changes have “been in development for many months, but due to increased stakeholder interest, we accelerated to announce now.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.